Design, synthesis and anticholinesterase activity of novel benzylidenechroman-4-ones bearing cyclic amine side chain. 2015

Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medicinal Sciences, Tehran 14176, Iran.

A series of 3-(4-(aminoalkoxy)benzylidene)-chroman-4-ones 7a-r were designed and synthesized as analogs of homoisoflavonoids which are well known natural products with diverse pharmacological properties related to Alzheimer's disease. The in vitro anti-cholinesterase activity of designed compounds 7a-r against AChE and BuChE, revealed that compounds bearing piperidinylethoxy residue showed potent activity against AChE at sub-micromolar level (IC50 values = 0.122-0.207 μM), more potent than reference drug tacrine. The structure-activity relationships study of piperidinylethoxy series demonstrated that the selectivity and physicochemical properties of compounds could be optimized by selection of a proper substituent on the C-7 position of chroman ring, while the high potency of the molecule against AChE was reserved.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D002867 Chromones 1,4-Benzopyrones,Chromone,1,4 Benzopyrones
D003500 Cyclization Changing an open-chain hydrocarbon to a closed ring. (McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Cyclizations
D000588 Amines A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amine
D001597 Benzylidene Compounds Compounds which include a double-bonded carbon atom that is directly attached to a benzene ring. While this category is named after the highly reactive compound benzylidene, the compounds listed under it occur through a variety of synthetic pathways. Benzylidene Compound,Benzylidene Derivative,Benzylidene Derivatives,Phenylmethylene Derivative,Phenylmethylene Derivatives,Compound, Benzylidene,Compounds, Benzylidene,Derivative, Benzylidene,Derivative, Phenylmethylene,Derivatives, Benzylidene,Derivatives, Phenylmethylene
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory
D020134 Catalytic Domain The region of an enzyme that interacts with its substrate to cause the enzymatic reaction. Active Site,Catalytic Core,Catalytic Region,Catalytic Site,Catalytic Subunit,Reactive Site,Active Sites,Catalytic Cores,Catalytic Domains,Catalytic Regions,Catalytic Sites,Catalytic Subunits,Core, Catalytic,Cores, Catalytic,Domain, Catalytic,Domains, Catalytic,Reactive Sites,Region, Catalytic,Regions, Catalytic,Site, Active,Site, Catalytic,Site, Reactive,Sites, Active,Sites, Catalytic,Sites, Reactive,Subunit, Catalytic,Subunits, Catalytic

Related Publications

Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
May 2017, Future medicinal chemistry,
Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
August 2011, The Journal of antibiotics,
Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
June 2000, Bioorganic & medicinal chemistry letters,
Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
August 2019, Molecular diversity,
Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
January 2015, European journal of medicinal chemistry,
Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
May 2020, Journal of agricultural and food chemistry,
Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
September 2008, Medicinal chemistry (Shariqah (United Arab Emirates)),
Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
January 2014, Drug research,
Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
May 2005, Bioorganic & medicinal chemistry letters,
Yaghoub Pourshojaei, and Ali Gouranourimi, and Shohre Hekmat, and Ali Asadipour, and Samira Rahmani-Nezhad, and Alireza Moradi, and Hamid Nadri, and Farshad Homayouni Moghadam, and Saeed Emami, and Alireza Foroumadi, and Abbas Shafiee
August 1998, Journal of peptide science : an official publication of the European Peptide Society,
Copied contents to your clipboard!